SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: SEPTEMBER 2, 1998
(Date of earliest event reported)
INCYTE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-27488 94-3136539
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
3174 PORTER DRIVE, PALO ALTO, CALIFORNIA 94304
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 855-0555
<PAGE>
Item 5. Other Events.
-------------
Disclosure regarding litigation involving Incyte Pharmaceuticals, Inc.
(the "Company") and its wholly owned subsidiary Synteni, Inc. ("Synteni") is
amended to reflect recent developments as follows:
In January 1998, Affymetrix, Inc. ("Affymetrix") filed a lawsuit in the
United States District Court for the District of Delaware alleging
infringement of U.S. patent number 5,445,934 (the "'934 Patent") by both
Synteni and Incyte. The complaint alleges that the '934 Patent has been
infringed by the making, using, selling, importing, distributing or offering
to sell in the U.S. high density arrays by Synteni and Incyte and that such
infringement was willful. Affymetrix seeks a permanent injunction enjoining
Synteni and Incyte from further infringement of the '934 Patent and, in
addition, seeks damages, costs and attorney's fees and interest. Affymetrix
further requests that any such damages be trebled based on its allegation of
willful infringement by Incyte and Synteni.
In September 1998 Affymetrix filed an additional lawsuit in the United
States District Court for the District of Delaware alleging infringement of
U.S. patent number 5,800,992 (the "'992 Patent") and U.S. patent number
5,744,305 (the "'305 Patent") by both Synteni and Incyte. The complaint
alleges that the '305 Patent has been infringed by the making, using, selling,
importing, distributing or offering to sell in the U.S. high density arrays by
Synteni and Incyte, that the '992 Patent has been infringed by the use of
Synteni's and Incyte's GEM microarray technology to conduct gene expression
monitoring using two-color labeling, and that such infringement was willful.
Affymetrix seeks a permanent injunction enjoining Synteni and Incyte from
further infringement of the '305 and '992 Patents and, in addition, seeks
damages, costs and attorney's fees and interest. Affymetrix further requests
that any such damages be trebled based on its allegation of willful
infringement by Incyte and Synteni. In addition, Affymetrix seeks a
preliminary injunction enjoining Incyte and Synteni from using Synteni's and
Incyte's GEM microarray technology to conduct gene expression monitoring using
two-color labeling.
Incyte and Synteni believe they have meritorious defenses and intend to
defend the suits vigorously. However, there can be no assurance that Incyte
and Synteni will be successful in the defense of these suits. Regardless of
the outcome, this litigation has resulted and, if a settlement is not reached,
is expected to continue to result in substantial expenses and diversion of the
efforts of management and technical personnel. Further, there can be no
assurance that any license that may be required as a result of these suits or
the outcome thereof would be made available on commercially acceptable terms,
if at all.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: September 2, 1998.
INCYTE PHARMACEUTICALS, INC.
By /s/ Denise Gilbert
--------------------
Name: Denise Gilbert
Title: Executive Vice President and
Chief Financial Officer
